Lecture

Department of Cardiology, USZ

The FOURIER Trial – Further Cardiovascular OUTcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

Thursday, 30.03.2017, 17:00–18:00
Kleiner Hörsaal Ost, UniversitätsSpital Zürich, Gloriastrasse 29, 8091 Zürich

Robert Patrick Giugliano, MD, MSc
Associate Professor of Medicine, Harvard Medical School
Brigham and Women’s Hospital
Division of Cardiovascular Medicine, Boston

Prof. Robert P. Giugliano is a cardiovascular medicine specialist at Brigham and Women’s Hospital (BWH), Division of Cardiovascular Medicine, Boston and an associate professor of medicine at Harvard Medical School (HMS). In addition, he is a senior investigator of BWH’s Thrombolysis in Myocardial Infarction (TIMI) Study Group.

Prof. Giugliano’s clinical interests include coronary artery disease, atrial fibrillation, and lipids. His research focuses on novel antithrombotic agents and lipid-lowering therapies to prevent cardiovascular disease. Outside of his work with the TIMI Study Group, he collaborates with independent research groups nationally and internationally to study novel therapies, clinical practice guidelines, and risk stratification in patients with acute coronary syndromes, atrial fibrillation and hyperlipidemia. He has authored over 250 peer-reviewed articles and chapters, serves as a reviewer and/or Editorial Board for over two dozen journals, and has delivered hundreds of lectures throughout the US and abroad.

FOURIER is a multinational Phase 3 double-blind, randomized, placebo-controlled trial in approximately 27,500 patients who had either a myocardial infarction, an ischemic stroke or symptomatic peripheral artery disease and an LDL ≥70 mg/dL or a non-HDL-C ≥100 mg/dL on optimized statin therapy, defined as at least atorvastatin 20 mg or equivalent daily with a recommendation for at least atorvastatin 40 mg or equivalent daily where approved. Patients were randomized to receive Repatha subcutaneous 140 mg every two weeks or 420 mg monthly or placebo subcutaneous every two weeks or monthly. The study continued until at least 1,630 patients experienced a key secondary major adverse cardiac event endpoint of cardiovascular death, myocardial infarction or stroke, whichever occurred first. Detailed results from the FOURIER outcomes trial will be presented at the American College of Cardiology (ACC) in Washington, D.C. on Friday, 17 March 2017.